efavirenz and HIV

efavirenz has been researched along with HIV in 112 studies

Research

Studies (112)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (3.57)	18.2507
2000's	41 (36.61)	29.6817
2010's	54 (48.21)	24.3611
2020's	13 (11.61)	2.80

Authors

Authors	Studies
Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P	1
Anand, B; Bal, TR; Sriram, D; Yogeeswari, P	1
Barreca, ML; Benkestock, K; Chimirri, A; Christ, F; De Luca, L; Debyser, Z; Eneroth, A; Ferro, S; Hombrouck, A; Johansson, NG; Michiels, M; Noppe, W; Sahlberg, BL; Van Remoortel, B; Vrang, L; Witvrouw, M	1
Allan, G; Barba, O; Burt, C; Corbau, R; Dupont, T; Irving, S; Jones, LH; Knöchel, T; Middleton, DS; Mowbray, CE; Perros, M; Phillips, C; Ringrose, H; Swain, NA; Webster, R; Westby, M	1
Boland, S; Cauvin, C; de Walque, S; Demonté, D; Durant, F; Georges, B; Hevesi, L; Le Van, K; Martinelli, V; Van Lint, C	1
Andries, K; Benjahad, A; de Béthune, MP; Decrane, L; Grierson, DS; Guillemont, J; Hertogs, K; Nguyen, CH; Oumouch, S; Palandjian, P; Queguiner, L; Vernier, D	1
Botta, M; Brai, A; Canducci, F; Ceresola, ER; Clementi, M; Corona, A; Esposito, F; Grandi, N; Tintori, C; Tramontano, E	1
Ashok, P; Chander, S; Murugesan, S; Wang, P; Yang, LM; Zheng, YT	1
Elgaher, WA; Hartmann, RW; Haupenthal, J; Mély, Y; Pires, M; Real, E; Saladini, F; Sharma, KK	1
Chen, FE; Gu, SX; Liu, GY; Meng, G; Pannecouque, C; Tang, JF; Wu, FS; Xiao, T; Xu, ZQ; Zhu, YY	1
De Clercq, E; Gao, P; Liu, X; Pannecouque, C; Song, S; Sun, L; Wang, Z; Zhan, P; Zhang, J	1
Adankie, BT; Aklillu, E; Amogne, W; Engidawork, E; Shibeshi, W; Tadesse, WT	1
Aarnoutse, R; Aber, F; Alinaitwe, L; Buzibye, A; Denti, P; Dooley, KE; Gausi, K; Kengo, A; Lamorde, M; Musaazi, J; Nabisere, R; Najjemba, L; Nampala, J; Omali, D; Otaalo, B; Sekaggya-Wiltshire, C; Sloan, DJ	1
Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z	1
Adimora, AA; Althoff, KN; Cole, SR; Edwards, JK; Eron, JJ; Gebo, K; Gill, MJ; Horberg, MA; Hudgens, MG; Jetsupphasuk, M; Kitahata, MM; Lang, R; Lima, VD; Lu, H; Marconi, VC; Moore, RD; Rabkin, C; Rebeiro, PF; Silverberg, MJ; Sterling, TR	1
Mendicino, CCP; Pádua, CAM; Silva, GJD; Tupinambás, U	1
Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H	1
Amara, A; Byakika-Kibwika, P; Byamugisha, J; Coombs, JA; Else, L; Gini, J; Heiburg, C; Hill, A; Hodel, EM; Kaboggoza, J; Khoo, S; Kintu, K; Lamorde, M; Malaba, T; Mehta, U; Myer, L; Orrell, C; Reynolds, H; Sihlangu, M; Simmons, B; Singh, Y; Waitt, C; Walimbwa, S	1
George, PE; Mercedes, R; Nabukeera-Barungi, N; Otto, SBJ	1
Bhattacharya, D; Chaktoura, N; Chipato, T; Currier, JS; Dula, D; Fowler, MG; George, K; Gnanashanmugam, D; Gupta, A; Huang, S; Klingman, KL; Martinson, F; Mohtashemi, N; Peters, MG; Tierney, C	1
Jianwei, L; Menghua, W; Qinwei, Y; Xin, Z; Yu, Z	1
Eriksson, LE; Marrone, G; Mellgren, Å; Reinius, M; Svedhem, V	1
Bengtson, AM; Cole, SR; Collier, AC; Crane, HM; Eaton, EF; Edwards, JK; Mathews, WC; Mollan, KR; O'Cleirigh, C; Pence, BW; Tierney, C; Weideman, AMK; Westreich, D; Xu, S	1
Aniceto, N; Antunes, F; Cruz, JP; Duarte, H; Fernandes, A; Morais, J; Paixão, P; Ribeiro, AC	1
Dahl, ML; Eriksen, J; Gustafsson, LL; Navér, L; Österberg, E; Rubin, J; Soeria-Atmadja, S	1
Jordaan, MA; Shapi, M	1
de Mast, Q; Kinabo, GD; Mchaile, DN; Schellekens, AFA; Van de Wijer, L; van der Ven, AJAM	1
Abrams, EJ; Coovadia, A; Hunt, G; Kuhn, L; Mbete, N; Murnane, PM; Patel, F; Shiau, S; Strehlau, R	1
Chen, X; Fairley, CK; He, J; Jing, J; Mao, L; Sasadeusz, J; Su, S; Wei, X; Zeng, H; Zhang, L	1
Aweeka, FT; Jagannathan, P; Kajubi, R	1
Srinivas, NR	1
Johnston, J; Joubert, A; Orrell, C; Smith, P; Wiesner, L	1
Acosta, EP; Bradford, Y; Daar, ES; Eron, JJ; Gulick, RM; Haas, DW; Morse, GD; Riddler, SA; Ritchie, MD; Sax, PE; Verma, A; Verma, SS	1
Bangsberg, DR; Boum, Y; Bwana, B; Chang, JL; Haberer, JE; Hunt, PW; Kroetz, DL; Lee, SA; Martin, J; Musinguzi, N; Muzoora, C; Siedner, MJ; Tsai, AC	1
Tartaglia, A	1
Avenant, T; du Plessis, N; George, J; Goga, AE; Mazanderani, AH; Murray, TY; Pepper, MS; Sherman, GG; Snyman, T	1
Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N	1
Arnett, DK; Bagchi, S; Chi, BH; Heimburger, DC; Kabagambe, EK; Kiage, JN; Koethe, JR; Nyirenda, CK; Wellons, MF	1
Sukasem, C; Sungkanuparph, S	1
Cabrera Figueroa, S; Carracedo Álvarez, A; Cruz Guerrero, R; Hurlé, AD; Hurtado, LP; Sánchez Martín, A	1
Heger, M	1
Holla, P; Jameel, S; Munshi, SU; Panda, H; Rewari, BB	1
Calvo Hernández, MV; Figueroa, SC; García-Berrocal, B; Gómez, AI; Gonzalez-Buitrago, JM; Isidoro-García, M; Martín, AF; Martín, AS; Sánchez, MC; Tovar, CB; Valverde Merino, MP	1
Berhanu, R; Brennan, AT; Fox, MP; Long, L; Maskew, M; Sanne, I; Shearer, K	1
Back, DJ; Burger, D; Lamorde, M; Schapiro, JM	1
Calvez, V; Desire, N; Girard, PM; Katlama, C; Marcelin, AG; Mercier-Darty, M; Morand-Joubert, L; Rodriguez, C; Todesco, E; Wirden, M	1
Bader, J; Glass, TR; Klimkait, T; Labhardt, ND; Lejone, TI; Puga, D; Ringera, I	1
Amin, J; Back, D; Boffito, M; Carey, D; Clarke, A; Cooper, DA; Dickinson, L; Egan, D; Else, L; Emery, S; Khoo, S; Losso, M; Orrell, C; Owen, A; Phanuphak, P; Puls, R	1
Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K	1
Dickinson, L; Owen, A; Siccardi, M	1
Bangsberg, D; Bienczak, A; Cohen, K; Denti, P; Maartens, G; Orrell, C; Wood, R	1
Belyhun, Y; Liebert, UG; Maier, M	1
Borghetti, A; Castagna, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Galizzi, N; Gianotti, N; Gori, A; Maillard, M; Mondi, A; Poli, A	1
Boulle, A; Cohen, K; Davies, MA; de Waal, R; Fortuin-de Smidt, M; Igumbor, EU; Maartens, G; Stinson, K; Technau, KG	1
Hallenberger, S; Jochmans, D; Lavens, D; Lemmens, I; Lievens, S; Pattyn, E; Tavernier, J; Van der Heyden, J; Verhee, A	1
Delsol, E; Gutiérrez, C; Hernández, B; Moreno, S	1
Avalos, A; Essex, M; Gaolathe, T; Hughes, MD; Mboya, JJ; Moffat, HJ; Ndwapi, N; Shapiro, RL; Shipton, LK; Stock, S; Thior, I; Wester, CW; Widenfelt, E	1
Burrell, CJ; Carr, JM; Daly, L; Green, T; Hart, W; Higgins, G; Li, P; Qiao, M; Ratcliff, R; Shaw, D	1
Airoldi, M; Cossarizza, A; De Biasi, S; Gibellini, L; Maggiolo, F; Mussini, C; Nasi, M; Pinti, M; Ravasio, V; Roat, E; Suter, F	1
Avihingsanon, A; Belloso, WH; Boesecke, C; Cooper, DA; Duncombe, C; Emery, S; Gazzard, B; Li, L; Molina, JM; Petoumenos, K; Puls, RL; Srasuebkul, P	1
Bachani, D; Chan, PL; Deshpande, A; Rajasekaran, S; Rewari, BB; Srikantiah, P	1
Dhlomo, S; Emery, S; Grandits, G; Khabo, P; Khanyile, T; Komati, S; Magongoa, D; Naidoo, LC; Neaton, JD; Polis, M; Qolohle, D; Ratsela, A	1
Giuliano, M; Marazzi, MC; Nielsen-Saines, K; Palombi, L	1
Boima, V; Flanigan, TP; Kenu, E; Kwara, A; Lartey, M; Mingle, JA; Oliver-Commey, J; Sagoe, A; Sagoe, KW; Seshie, M; Wu, H; Xexemeku, F; Yang, H	1
Dewar, RL; Dlamini, JN; Follmann, DA; Highbarger, HC; Hu, Z; Pau, AK; Somaroo, H	1
Chiappetta, DA; de Celis, ER; Facorro, G; Sosnik, A	1
DiFrancesco, R; Fischl, MA; Forrest, A; Gripshover, BM; Luque, AE; Ma, Q; Morse, GD; Venuto, CS; Zingman, BS	1
Abrams, EJ; Coovadia, A; Dandara, C; Kuhn, L; Maisel, J; Martens, L; Norman, J; Strehlau, R	1
Abgrall, S; Bommenel, T; Costagliola, D; Gilquin, J; Katlama, C; Lascaux, AS; Launay, O; Mahamat, A; Martinez, V; Meynard, JL; Pradier, C; Rouveix, E; Simon, A	1
Kuhn, L; Meyers, TM; Moultrie, H; Yotebieng, M	1
Aleixo, AW; Arruda, MB; de M Brindeiro, R; Greco, DB; Martins, AN; Pires, AF; Tanuri, A	1
Durant, J; Duvivier, C; Fätkenheuer, G; Hill, A; Marks, S; Rey, D; Rieger, A; Schmidt, W; van Delft, Y	1
Back, D; Dickinson, L; Watson, V; Yilmaz, A	1
Krogstad, PA; Marsden, MD; Zack, JA	1
Back, D; Battegay, M; de Roche, M; Livio, F; Marzolini, C; Siccardi, M; Stoeckle, M	1
Lefebvre, J; Levin, P; Perkins, TJ	1
Ahluwalia, J; Ananworanich, J; Chaithongwongwatthana, S; Gorowara, M; Kriengsinyot, R; Landolt, NK; Lange, JM; Phanuphak, N; Pinyakorn, S; Thammajaruk, N; Thongpaeng, P; Ubolyam, S	1
Biasin, M; Clerici, M; Di Pietro, M; Lo Caputo, S; Maserati, R; Mazzotta, F; Ravasi, G; Seminari, E; Trabattoni, D	1
Bakshi, KK; Chen, J; Condra, JH; Danovich, RM; DiNubile, MJ; Graham, DJ; Haas, DW; Holder, DJ; Rhodes, RR; Saah, AJ; Shivaprakash, M	1
Desta, Z; Flockhart, DA; Gorski, JC; Hall, SD; Jones, DR; Ward, BA	1
Bowonwatanuwong, C; Chantratita, W; Chetchotisakd, P; Mootsikapun, P; Sungkanuparph, S; Tansuphaswaswadikul, S; Vibhagool, A	1
Bouvet, E; Descamps, D; Larouzé, B; Massari, V; Parienti, JJ; Vabret, A; Verdon, R	1
Bordenave, B; Claxton, S; Henry, K; Kane, E; Klebert, M; Powderly, WG; Tebas, P; Yarasheski, K	1
Boeri, E; Castagna, A; Gallotta, G; Gianotti, N; Maillard, M; Ratti, D; Serra, G; Tremolada, Y; Vacchini, D	1
Havlir, DV; Ignacio, CC; Koelsch, KK; Lu, B; Margot, N; Miller, MD; Strain, MC; Wong, JK	1
Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L	1
Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ	1
Beerenwinkel, N; Drton, M	1
Antoniadou, A; Giamarellou, H; Katsarolis, I; Panagopoulos, P; Papadopoulos, A; Poulakou, G; Tsiodras, S	1
Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O	1
Hansen, AB; Justesen, US; Mathiesen, S; Von Lüttichau, HR	1
Breilh, D; Camou, F; Caubet, O; Djabarouti, S; Fleury, H; Lavit, M; Pellegrin, I; Pellegrin, JL; Saux, MC	1
de Campos, AV; Leon, E; Lopez-Cortes, LF; Lozano, F; Marin-Niebla, A; Marquez-Solero, M; Ruiz-Morales, J; Ruiz-Valderas, R; Valiente, R	1
Aubertin, AM; Burrer, R; Einius-Haessig, S; Moog, C; Pancino, G; Richert, S; Salmon-Ceron, D; Spiridon, G	1
Aguilar, I; Hidalgo, A; Palacios, R; Santos, J	1
Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P	1
Cecelia, AJ; Devaleenal, B; Flanigan, T; Kumarasamy, N; Mayer, KH; Muthu, S; Palanivel, V; Venkatesh, KK; Yepthomi, T	1
Gulick, RM; Kuritzkes, DR; Ribaudo, HJ	1
Abbara, C; Barrail, A; Boissonnas, A; Bonhomme-Faivre, L; Duclos-Vallée, JC; Samuel, D; Taburet, AM; Teicher, E; Vincent, I; Vittecoq, D	1
Asensi, V; Barreiro, P; de Mendoza, C; Estrada, V; González-Lahoz, J; Jiménez-Nacher, I; Palacios, R; Rivas, P; Rodríguez-Novoa, S; Sánchez-Conde, M; Santos, J; Sanz, J; Sola, J; Soriano, V	1
Chen, J; Cooper, DA; Emery, S; Hazuda, DJ; Kelleher, AD; Law, M; Murray, JM; Nguyen, BY; Teppler, H	1
Cordova, B; Jackson, DA; Rayner, MM	1
Collier, AC; Schwartz, MA	1
Chen, CY; Tan, L	1
Duval, X	1
Belec, L; Castiel, P; Clavel, F; Gonzalez-Canali, G; Kazatchkine, MD; Peytavin, G; Piketty, C; Race, E; Si-Mohamed, A; Weiss, L	1
Baird, BF; Chun, TW; Dybul, M; Engel, D; Fauci, AS; Fox, CH; Green, LG; Hertogs, K; Larder, B; Li, Y; Liu, S; Mican, JM; Orenstein, JM; Ward, DJ	1
Barry, M; Clarke, S; Harrington, P; Mulcahy, F	1

Reviews

5 review(s) available for efavirenz and HIV

Article	Year
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6 Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Genome, Viral; HIV; HIV Infections; Humans; Interdisciplinary Communication; Models, Molecular; Molecular Structure; Mutation; Nitriles; Pyrimidines; Rilpivirine	2005
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach. AIDS (London, England), 2014, Nov-13, Volume: 28, Issue:17 Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Viral; Drug Therapy; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Public Health; Tenofovir	2014
[Maraviroc efficacy in clinical studies on the development of the molecule]. Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 11 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Cyclohexanes; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Design; Drug Resistance, Multiple, Viral; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Multicenter Studies as Topic; Salvage Therapy; Treatment Outcome; Triazoles	2008
Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients. Expert review of anti-infective therapy, 2006, Volume: 4, Issue:6 Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Oxazines; Quality of Life; Reverse Transcriptase Inhibitors	2006
Strategies for second-line antiretroviral therapy in adults with HIV infection. Advances in experimental medicine and biology, 1999, Volume: 458 Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Virus Latency; Virus Replication	1999

Trials

25 trial(s) available for efavirenz and HIV

Article	Year
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3 Topics: Anti-HIV Agents; Benzoxazines; HIV; HIV Infections; Humans; Rifampin; Tuberculosis	2023
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3 Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Pulmonary	2023
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS medicine, 2019, Volume: 16, Issue:9 Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Maternal-Fetal Exchange; Milk, Human; Oxazines; Piperazines; Pregnancy; Pyridones; Reverse Transcriptase Inhibitors; Risk Assessment; South Africa; Treatment Outcome; Uganda; Viral Load; Young Adult	2019
Hepatotoxicity and Liver-Related Mortality in Women of Childbearing Potential Living With Human Immunodeficiency Virus and High CD4 Cell Counts Initiating Efavirenz-Containing Regimens. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 04-26, Volume: 72, Issue:8 Topics: Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV; HIV Infections; Humans; Infant; Pregnancy	2021
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenetics and genomics, 2018, Volume: 28, Issue:7 Topics: Adult; Alkynes; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Female; Genomics; Genotype; HIV; HIV Infections; Humans; Male; Middle Aged; Neurotransmitter Transport Proteins; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Receptors, Neurotransmitter; Reverse Transcriptase Inhibitors	2018
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study. Clinical pharmacology and therapeutics, 2015, Volume: 98, Issue:4 Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biomarkers; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Drug Administration Schedule; Female; Genotype; HIV; HIV Infections; Humans; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Young Adult	2015
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients. Antiviral therapy, 2010, Volume: 15, Issue:1 Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir	2010
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Oct-01, Volume: 51, Issue:7 Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine	2010
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa. The Journal of infectious diseases, 2010, Nov-15, Volume: 202, Issue:10 Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; South Africa; Stavudine; Treatment Outcome; Zidovudine	2010
Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders. Therapeutic drug monitoring, 2011, Volume: 33, Issue:3 Topics: Alkynes; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Monitoring; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; RNA, Viral; Substance-Related Disorders	2011
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:8 Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Prospective Studies; Treatment Outcome; Viral Load	2011
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:3 Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Double-Blind Method; Female; HIV; HIV Infections; Humans; Lipids; Male; Middle Aged; Nitriles; Placebos; Pyridazines; Pyrimidines; Viral Load; Young Adult	2012
Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. Journal of acquired immune deficiency syndromes (1999), 2013, Apr-15, Volume: 62, Issue:5 Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptives, Oral, Synthetic; Cyclopropanes; Desogestrel; Drug Interactions; Ethinyl Estradiol; Female; HIV; HIV Infections; Humans; Logistic Models; Middle Aged; Nevirapine; Progesterone; Prospective Studies; Thailand; Young Adult	2013
Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. Clinical and diagnostic laboratory immunology, 2002, Volume: 9, Issue:5 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interferon-gamma; Interleukin-10; Interleukin-2; Male; Nelfinavir; Oxazines; Random Allocation; RNA, Messenger; Stavudine; Treatment Failure	2002
Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy. The Journal of infectious diseases, 2003, Apr-01, Volume: 187, Issue:7 Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Organophosphonates; Oxazines; Treatment Failure	2003
Efavirenz-based regimen as treatment of advanced AIDS with cryptococcal meningitis. Journal of acquired immune deficiency syndromes (1999), 2003, May-01, Volume: 33, Issue:1 Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cryptococcus neoformans; Cyclopropanes; Female; HIV; Humans; Male; Meningitis, Cryptococcal; Oxazines; RNA, Viral; Thailand; Time Factors	2003
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS research and human retroviruses, 2004, Volume: 20, Issue:6 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Body Composition; Bone Density; C-Peptide; Cyclopropanes; Drug Therapy, Combination; Female; Glucagon; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Insulin; Insulin Resistance; Lipids; Lipoproteins; Male; Nevirapine; Oxazines; Pilot Projects; RNA, Viral; Viral Load	2004
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3 Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Zidovudine	2006
Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. The Journal of antimicrobial chemotherapy, 2006, Volume: 58, Issue:5 Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis	2006
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. Journal of acquired immune deficiency syndromes (1999), 2007, Aug-15, Volume: 45, Issue:5 Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine	2007
Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting. Journal of acquired immune deficiency syndromes (1999), 2007, Aug-15, Volume: 45, Issue:5 Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Costs and Cost Analysis; Cyclopropanes; Female; HIV; HIV Infections; Humans; India; Liver; Liver Diseases; Male; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome	2007
A comparison of three initial antiretroviral AIDS regimens. The New England journal of medicine, 2007, Sep-06, Volume: 357, Issue:10 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine	2007
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clinical pharmacokinetics, 2007, Volume: 46, Issue:11 Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Female; Graft Rejection; Half-Life; Hepatitis C; HIV; HIV Infections; Humans; Liver Transplantation; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Tacrolimus; Viral Load	2007
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS (London, England), 2007, Nov-12, Volume: 21, Issue:17 Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Linear Models; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Statistics, Nonparametric; Tenofovir; Time Factors; Viral Load; Virus Integration; Virus Latency; Virus Replication	2007
Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy. The Journal of infectious diseases, 2000, Volume: 181, Issue:4 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Coculture Techniques; Cross-Sectional Studies; Cyclopropanes; Genotype; HIV; HIV Infections; Humans; In Situ Hybridization; Lymph Nodes; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Virus Replication	2000

Other Studies

82 other study(ies) available for efavirenz and HIV

Article	Year
Synthesis and evaluation of anti-HIV activity of isatin beta-thiosemicarbazone derivatives. Bioorganic & medicinal chemistry letters, 2005, Oct-15, Volume: 15, Issue:20 Topics: Cell Line; HIV; Humans; Isatin; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Models, Molecular; Reverse Transcriptase Inhibitors	2005
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:8 Topics: Anti-HIV Agents; Caco-2 Cells; Cell Line, Tumor; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; HIV; HIV Integrase Inhibitors; Humans; Indoles; Integrases; Molecular Structure; Polymerase Chain Reaction; Viral Proteins; Virus Replication	2008
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays. Journal of medicinal chemistry, 2009, Feb-26, Volume: 52, Issue:4 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Crystallography, X-Ray; Cyclopropanes; Drug Design; Drug Resistance, Viral; Drug Stability; HIV; HIV Reverse Transcriptase; Humans; Imidazoles; Indazoles; Molecular Structure; Mutation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfur Compounds	2009
New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors. Journal of medicinal chemistry, 2009, Jun-25, Volume: 52, Issue:12 Topics: Anti-HIV Agents; Binding Sites; Cell Line; Cell Survival; Cell Transformation, Viral; Computer Simulation; Crystallography, X-Ray; HIV; HIV Reverse Transcriptase; Humans; Microbial Sensitivity Tests; Models, Chemical; Models, Molecular; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship	2009
Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents. Journal of medicinal chemistry, 2009, Dec-10, Volume: 52, Issue:23 Topics: Anti-HIV Agents; Cell Line; HIV; HIV Reverse Transcriptase; Humans; Inhibitory Concentration 50; Iodopyridones; Mutation; Small Molecule Libraries	2009
Inhibition of HIV-1 Reverse Transcriptase Dimerization by Small Molecules. Chembiochem : a European journal of chemical biology, 2016, Apr-15, Volume: 17, Issue:8 Topics: Anti-HIV Agents; Enzyme Activation; Enzyme Stability; HIV; HIV Reverse Transcriptase; Models, Molecular; Molecular Structure; Protein Multimerization; Reverse Transcriptase Inhibitors; Small Molecule Libraries; Structure-Activity Relationship; Temperature; Virus Replication	2016
Rational design, synthesis, anti-HIV-1 RT and antimicrobial activity of novel 3-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-1-(piperazin-1-yl)propan-1-one derivatives. Bioorganic chemistry, 2016, Volume: 67 Topics: Anti-Bacterial Agents; Anti-HIV Agents; Antifungal Agents; Bacteria; Dose-Response Relationship, Drug; Drug Design; Fungi; HIV; HIV Reverse Transcriptase; Microbial Sensitivity Tests; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship	2016
Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors. Journal of medicinal chemistry, 2016, Aug-11, Volume: 59, Issue:15 Topics: Anti-Bacterial Agents; Anti-HIV Agents; Carboxylic Acids; DNA-Directed RNA Polymerases; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Escherichia coli; HEK293 Cells; HeLa Cells; HIV; Humans; Microbial Sensitivity Tests; Molecular Structure; RNA-Directed DNA Polymerase; Structure-Activity Relationship; Thiophenes	2016
Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities. European journal of medicinal chemistry, 2020, Jan-15, Volume: 186 Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Reverse Transcriptase; Humans; Indazoles; Microbial Sensitivity Tests; Molecular Structure; Piperidines; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship	2020
Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs. Bioorganic & medicinal chemistry, 2021, 06-15, Volume: 40 Topics: Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Reverse Transcriptase; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship	2021
Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy. PloS one, 2022, Volume: 17, Issue:1 Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Blood Glucose; Cross-Sectional Studies; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Ethiopia; Female; Glucose; Glucose Metabolism Disorders; HIV; HIV Infections; Humans; Insulin; Male; Prevalence; Ritonavir	2022
Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine. American journal of epidemiology, 2023, 08-04, Volume: 192, Issue:8 Topics: Acquired Immunodeficiency Syndrome; HIV; HIV Infections; Humans; Precision Medicine; Reverse Transcriptase Inhibitors	2023
Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens. Einstein (Sao Paulo, Brazil), 2023, Volume: 21 Topics: Adult; Anti-HIV Agents; Benzoxazines; Female; HIV; HIV Infections; Humans; Male; Viral Load	2023
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. PLoS medicine, 2023, Volume: 20, Issue:11 Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Isoniazid; Lopinavir; Male; Pyrazinamide; Rifampin; Ritonavir; Tuberculosis	2023
Cryptococcal meningitis and immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to second line antiretroviral therapy: a case report. BMC infectious diseases, 2020, Jan-21, Volume: 20, Issue:1 Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Antigens, Fungal; Benzoxazines; Child; Cryptococcus neoformans; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fluconazole; HIV; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Lopinavir; Meningitis, Cryptococcal; Ritonavir; Treatment Outcome; Viral Load; Zidovudine	2020
Case report: one case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a normal CD4 AIDS research and therapy, 2020, 07-23, Volume: 17, Issue:1 Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Betacoronavirus; C-Reactive Protein; CD4 Lymphocyte Count; Chills; Coronavirus Infections; COVID-19; Cyclopropanes; Fatigue; Female; Fever; HIV; HIV Infections; Humans; Immunocompromised Host; Immunoglobulin M; Lamivudine; Middle Aged; Pandemics; Pharyngitis; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; SARS-CoV-2; Sputum; Time Factors; Tomography, X-Ray Computed; Virus Shedding; Zidovudine	2020
Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study. PloS one, 2020, Volume: 15, Issue:12 Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Arthralgia; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Erectile Dysfunction; Female; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Nausea; Oxazines; Patient Reported Outcome Measures; Piperazines; Pyridones; Quality of Life; Registries; Sweden	2020
Transportability From Randomized Trials to Clinical Care: On Initial HIV Treatment With Efavirenz and Suicidal Thoughts or Behaviors. American journal of epidemiology, 2021, 10-01, Volume: 190, Issue:10 Topics: Adult; Alkynes; Anti-HIV Agents; Antidepressive Agents; Benzoxazines; Cyclopropanes; Depression; Drug Prescriptions; Female; HIV; HIV Infections; Humans; Incidence; Male; Observational Studies as Topic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Suicidal Ideation; Translational Research, Biomedical; United States	2021
Population Approach to Efavirenz Therapy. Journal of pharmaceutical sciences, 2017, Volume: 106, Issue:10 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Male; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors	2017
Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin. PloS one, 2017, Volume: 12, Issue:9 Topics: Age Factors; Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Ethnicity; Female; Gene Frequency; Genotype; HIV; HIV Infections; Humans; Male; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Sex Factors; Sweden; Viral Load	2017
Investigation of the solvent-dependent photolysis of a nonnucleoside reverse-transcriptase inhibitor, antiviral agent efavirenz. Antiviral chemistry & chemotherapy, 2017, Volume: 25, Issue:3 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV; Microbial Sensitivity Tests; Molecular Conformation; Photolysis; Reverse Transcriptase Inhibitors; Solvents	2017
Safety Evaluation of Efavirenz in Children: Don't Forget the Central Nervous System. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 03-19, Volume: 66, Issue:7 Topics: Alkynes; Benzoxazines; Child; Cyclopropanes; HIV; Humans; Lopinavir; Nervous System; Nevirapine; Ritonavir	2018
Reply to Van de Wijer et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 03-19, Volume: 66, Issue:7 Topics: Alkynes; Benzoxazines; Child; Cyclopropanes; HIV; Humans; Lopinavir; Nevirapine; Ritonavir	2018
HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome. Journal of medical virology, 2018, Volume: 90, Issue:3 Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies; Coinfection; Cyclopropanes; Female; Hepatitis B; Hepatitis C; HIV; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Retrospective Studies; Treatment Outcome; Viral Load; Zidovudine	2018
Response to "Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction". Clinical pharmacology and therapeutics, 2018, Volume: 103, Issue:4 Topics: Alkynes; Artemisinins; Benzoxazines; Chemoprevention; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; Humans; Malaria; Pregnancy; Quinolines	2018
Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction. Clinical pharmacology and therapeutics, 2018, Volume: 103, Issue:4 Topics: Alkynes; Artemisinins; Benzoxazines; Chemoprevention; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; Humans; Malaria; Pregnancy; Quinolines	2018
A validated liquid chromatography/tandem mass spectrometry method for the analysis of efavirenz in 0.2 mg hair samples from human immunodeficiency virus infected patients. Rapid communications in mass spectrometry : RCM, 2018, Apr-30, Volume: 32, Issue:8 Topics: Alkynes; Benzoxazines; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Female; Hair; HIV; HIV Infections; Humans; Limit of Detection; Male; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry	2018
CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies. AIDS research and human retroviruses, 2018, Volume: 34, Issue:11 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Depression; Female; Genotype; HIV; HIV Infections; Humans; Male; Odds Ratio; Polymorphism, Single Nucleotide; Prospective Studies; Uganda; Viral Load	2018
Multidrug nanosuspensions: future perspectives on drug delivery system for HIV combination antiretroviral therapy. AIDS (London, England), 2018, 11-13, Volume: 32, Issue:17 Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; Drug Delivery Systems; HIV; HIV Infections; Lopinavir; Primates; Tenofovir	2018
Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa. Journal of the International AIDS Society, 2019, Volume: 22, Issue:6 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; Cohort Studies; Cyclopropanes; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Nevirapine; Polymerase Chain Reaction; Prospective Studies; Reverse Transcriptase Inhibitors; South Africa; Tertiary Healthcare	2019
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. HIV medicine, 2013, Volume: 14, Issue:7 Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Black or African American; Cyclopropanes; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; Female; Frail Elderly; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; White People	2013
Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Lipids in health and disease, 2013, Apr-10, Volume: 12 Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Female; HIV; HIV Infections; Humans; Insulin Resistance; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Triglycerides; Zambia; Zidovudine	2013
Would a CYP2B6 test help HIV patients being treated with efavirenz? Pharmacogenomics, 2013, Volume: 14, Issue:9 Topics: Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Central Nervous System; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug-Related Side Effects and Adverse Reactions; Genotype; HIV; HIV Infections; Humans; Polymorphism, Single Nucleotide; Treatment Outcome	2013
Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics, 2013, Volume: 14, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biomarkers, Pharmacological; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide	2013
Trials challenging HIV drug doses could usher in huge cost cuts. Nature medicine, 2013, Volume: 19, Issue:8 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Costs and Cost Analysis; Cyclopropanes; Dose-Response Relationship, Drug; HIV; HIV Infections; Humans	2013
MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy. PloS one, 2014, Volume: 9, Issue:5 Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Drug Resistance, Viral; Female; Gene Expression Regulation; HIV; Humans; Lamivudine; Leukocytes, Mononuclear; Male; MicroRNAs; Nevirapine; Stavudine; Treatment Outcome; Viral Load; Zidovudine	2014
Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics. Pharmacogenomics, 2014, Volume: 15, Issue:7 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; Female; Genotype; HIV; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics	2014
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. Journal of the International AIDS Society, 2014, Volume: 17 Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Male; Middle Aged; Nevirapine; South Africa; Treatment Failure; Viremia; Young Adult	2014
Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:5 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Plasma; Tenofovir; Treatment Failure	2015
Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings? Tropical medicine & international health : TM & IH, 2015, Volume: 20, Issue:7 Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; Health Resources; HIV; HIV Infections; Humans; Lamivudine; Lesotho; Logistic Models; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Zidovudine	2015
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART). Current molecular medicine, 2015, Volume: 15, Issue:10 Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine	2015
Validation of Computational Approaches for Antiretroviral Dose Optimization. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:6 Topics: Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Administration Schedule; Drug Dosage Calculations; Gene Expression; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Models, Statistical; Mutation Rate	2016
Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy. International journal of antimicrobial agents, 2016, Volume: 47, Issue:6 Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; HIV; HIV Infections; Humans; Male; Plasma; Polymorphism, Genetic; RNA, Viral; Treatment Outcome; Viral Load	2016
HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia. Antiviral therapy, 2017, Volume: 22, Issue:2 Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Ethiopia; Female; Genetic Variation; Genome, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Immune Evasion; Lamivudine; Male; Mutation; Stavudine; Viral Load; Zidovudine	2017
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. The Journal of infection, 2016, Volume: 73, Issue:6 Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Emtricitabine; HIV; Humans; Lamivudine; Ritonavir; Tenofovir; United Kingdom	2016
First-line antiretroviral drug discontinuations in children. PloS one, 2017, Volume: 12, Issue:2 Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Follow-Up Studies; HIV; HIV Infections; Humans; Infant; Kaplan-Meier Estimate; Lopinavir; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; South Africa; Stavudine; Withholding Treatment; Zidovudine	2017
MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells. Journal of virological methods, 2008, Volume: 153, Issue:1 Topics: Alkynes; Benzoxazines; Cell Line; Cyclopropanes; Dimerization; HIV; HIV Reverse Transcriptase; Humans; Inhibitory Concentration 50; Protein Binding; Protein Interaction Mapping; Protein Subunits; Reverse Transcriptase Inhibitors	2008
Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2009, Volume: 13, Issue:3 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; CD4 Lymphocyte Count; Comorbidity; Cyclopropanes; Female; HIV; HIV Infections; Humans; Liver Function Tests; Male; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tuberculosis, Pulmonary	2009
Application of an allele-specific PCR to clinical HIV genotyping samples detects additional K103N mutations in both therapy naïve and experienced patients. Journal of medical virology, 2009, Volume: 81, Issue:12 Topics: Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genetic Variation; HIV; HIV Infections; Humans; Male; Molecular Diagnostic Techniques; Mutation, Missense; Polymerase Chain Reaction; RNA, Viral; Sensitivity and Specificity; Viral Load	2009
Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing. Journal of acquired immune deficiency syndromes (1999), 2010, Dec-15, Volume: 55, Issue:5 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV; HIV Infections; Humans; India; Lamivudine; Male; Middle Aged; Nevirapine; RNA, Viral; Stavudine; Treatment Failure; Viral Load; Zidovudine	2010
Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern. AIDS research and human retroviruses, 2011, Volume: 27, Issue:8 Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Child; Cyclopropanes; Female; Flow Cytometry; Global Health; HIV; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Nevirapine; Policy; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Public Health	2011
Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Feb-15, Volume: 52, Issue:4 Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Female; HIV; HIV Infections; Humans; Male; Tuberculosis; Viral Load; Viremia	2011
Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir. Pharmacotherapy, 2011, Volume: 31, Issue:2 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Clinical Trials, Phase II as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Pyrimidinones; Randomized Controlled Trials as Topic; Retrospective Studies; Ritonavir; RNA, Viral; South Africa; Young Adult	2011
Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles. Nanomedicine : nanotechnology, biology, and medicine, 2011, Volume: 7, Issue:5 Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Delivery Systems; Drug Synergism; Ethylenediamines; HIV; Humans; Micelles; Nanocapsules; Poloxamer; Solubility	2011
Absence seizures associated with efavirenz initiation. The Pediatric infectious disease journal, 2011, Volume: 30, Issue:11 Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Epilepsy, Absence; Female; Genetic Predisposition to Disease; Genotype; HIV; HIV Infections; Homozygote; Humans; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; South Africa; Viral Load	2011
Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa. The Pediatric infectious disease journal, 2011, Volume: 30, Issue:11 Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Coinfection; Cyclopropanes; Female; Follow-Up Studies; HIV; HIV Infections; Hospitals, Public; Humans; Infant; Lopinavir; Male; Mycobacterium tuberculosis; Recurrence; Ritonavir; South Africa; Survival Analysis; Tuberculosis, Pulmonary; Viral Load	2011
Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics. Journal of acquired immune deficiency syndromes (1999), 2011, Volume: 57 Suppl 3 Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cyclopropanes; Drug Resistance, Viral; HIV; HIV Infections; Humans; Mutation, Missense; Nevirapine; Nitriles; Prevalence; Pyridazines; Pyrimidines	2011
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:9 Topics: Alkynes; Anti-HIV Agents; Antifungal Agents; Area Under Curve; Benzoxazines; Chromatography, High Pressure Liquid; Coinfection; Cryptococcus neoformans; Cyclopropanes; Half-Life; HIV; HIV Infections; Humans; Male; Meningitis, Cryptococcal; Middle Aged; Tandem Mass Spectrometry	2012
Virological evidence supporting the use of raltegravir in HIV post-exposure prophylaxis regimens. Antiviral therapy, 2012, Volume: 17, Issue:7 Topics: Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Gene Expression Regulation, Viral; Genes, Reporter; Genes, Viral; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Luciferases; Macrophages; Microbial Sensitivity Tests; Post-Exposure Prophylaxis; Pyrrolidinones; Raltegravir Potassium; Time Factors	2012
Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing. Antiviral therapy, 2012, Volume: 17, Issue:7 Topics: Alkynes; Benzoxazines; Body Mass Index; Computer Simulation; Cyclopropanes; Drug Dosage Calculations; Drug Monitoring; HIV; HIV Infections; Humans; Male; Middle Aged; Obesity; Reverse Transcriptase Inhibitors; Risk Factors; RNA, Viral; Viral Load	2012
What do molecules do when we are not looking? State sequence analysis for stochastic chemical systems. Journal of the Royal Society, Interface, 2012, Dec-07, Volume: 9, Issue:77 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genome, Viral; HIV; Markov Chains; Mutation; Probability; Sodium Channels; Software; Stochastic Processes	2012
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. The Journal of pharmacology and experimental therapeutics, 2003, Volume: 306, Issue:1 Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biotransformation; Catalysis; Cyclopropanes; Cytochrome P-450 CYP2B6; HIV; HIV Infections; Humans; Microsomes, Liver; Oxazines; Oxidoreductases, N-Demethylating; Recombinant Proteins	2003
Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, May-01, Volume: 38, Issue:9 Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Forecasting; Guideline Adherence; HIV; HIV Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nevirapine; Oxazines; Treatment Failure; Viral Load	2004
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results. The new microbiologica, 2004, Volume: 27, Issue:2 Suppl 1 Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Delavirdine; DNA, Complementary; Drug Resistance, Viral; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Selection, Genetic; Viremia	2004
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. The Journal of infectious diseases, 2005, Apr-01, Volume: 191, Issue:7 Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Oxazines; RNA, Viral; Stavudine; Tenofovir; Viremia	2005
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. The Journal of infection, 2006, Volume: 52, Issue:2 Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Ghana; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mycobacterium tuberculosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Tuberculosis	2006
A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data. Biostatistics (Oxford, England), 2007, Volume: 8, Issue:1 Topics: Alkynes; Benzoxazines; Clone Cells; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; HIV; HIV Infections; Humans; Longitudinal Studies; Markov Chains; Models, Genetic; Oxazines; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA	2007
Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2006, Volume: 12, Issue:5 Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Oxazines; Pyrimidinones; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Triglycerides; Viral Load	2006
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. European journal of clinical pharmacology, 2006, Volume: 62, Issue:7 Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir	2006
Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects. Scandinavian journal of infectious diseases, 2006, Volume: 38, Issue:8 Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; Genotype; HIV; HIV Infections; Humans; Lopinavir; Male; Oxazines; Oxidoreductases, N-Demethylating; Pyrimidinones	2006
Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study). The Journal of antimicrobial chemotherapy, 2006, Volume: 58, Issue:5 Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral	2006
Efavirenz in plasma from HIV-infected patients does not directly block reverse transcriptase activity in cell-free assays but inhibits HIV replication in cellular assays. AIDS research and human retroviruses, 2006, Volume: 22, Issue:9 Topics: Alkynes; Benzoxazines; Blood Proteins; Cell Culture Techniques; Cyclopropanes; HIV; Humans; Immunoglobulin G; Leukocytes, Mononuclear; Oxazines; Protein Binding; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Virus Replication	2006
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study. AIDS research and human retroviruses, 2007, Volume: 23, Issue:10 Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Administration Schedule; Female; Food; HIV; HIV Infections; Humans; Lamivudine; Male; Spain; Viral Load	2007
Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections. Virology, 1997, Sep-15, Volume: 236, Issue:1 Topics: Alkynes; Azepines; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Microbial Sensitivity Tests; Oxazines; Population Dynamics; Reverse Transcriptase Inhibitors; Time Factors; Urea; Viral Plaque Assay	1997
[DuPont-Pharma Laboratories. Sustiva]. Allergie et immunologie, 1998, Volume: 30, Issue:9 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Brain; Cerebrospinal Fluid; Cyclopropanes; HIV; HIV Infections; Humans; Oxazines; RNA, Viral	1998
Chemical process evolution of efavirenz, a potent non-nucleosidal HIV reverse transcriptase inhibitor. Enantiomer, 1999, Volume: 4, Issue:6 Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV; Models, Molecular; Molecular Structure; Oxazines; Reverse Transcriptase Inhibitors; Stereoisomerism	1999
[The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage]. Presse medicale (Paris, France : 1983), 2000, Feb-12, Volume: 29, Issue:5 Topics: Alkynes; Animals; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Time Factors; Uracil; Viral Load	2000
Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz. AIDS (London, England), 2000, Mar-31, Volume: 14, Issue:5 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Phenotype; Ritonavir; Saquinavir; Treatment Failure	2000
The tolerability of efavirenz after nevirapine-related adverse events. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000, Volume: 31, Issue:3 Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Anxiety Disorders; Benzoxazines; Cyclopropanes; Female; HIV; HIV Infections; Homosexuality; Humans; Male; Middle Aged; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors	2000
[Positive change from protease inhibitor to non-nucleoside reverse transcriptase inhibitor efavirenz. Improved virus control thanks to protease inhibitor switch]. MMW Fortschritte der Medizin, 2001, Apr-02, Volume: 143 Suppl 1 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; Humans; Oxazines	2001
[Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor]. MMW Fortschritte der Medizin, 2001, Apr-02, Volume: 143 Suppl 1 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; HIV; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome	2001
Efavirenz (Sustiva). Research initiative, treatment action : RITA, 2000, Volume: 6, Issue:1 Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; HIV; HIV Infections; Humans; Oxazines; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors	2000